# A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

> **NCT04171700** · PHASE2 · TERMINATED · sponsor: **pharmaand GmbH** · enrollment: 83 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT04171700
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-16
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-07-15
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** The study was terminated due to a change in development priorities.
- **Last updated:** 2023-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04171700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04171700, "A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT04171700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*